Dean, O., Giorlando, F., & Berk, M
The body essentially adapts to the presence of the signaling molecule and requires increasingly higher doses to achieve the same effect
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
So, while we dont get much B12 in the water anymore, we dont get much cholera, either, which is a good thing
If you have concerns about pain or side effects, our team is happy to discuss these with you before your treatment, ensuring you feel informed and comfortable every step of the way
Why Choose Aesthetica Med Spa in San Diego